Nilai Buku saben Saham: enveric.com (ENVB)

The absence of recurring revenue makes the credit profile of Enveric Biosciences (ENVB) dependent on grants and trials. The book value per share exhibits moderate volatility, with the parameter reaching 2.07. Risks are linked to R&D costs and therapeutic uncertainty, although the high valuation of the Psybrary platform sustains investor confidence in innovative neuroplastogens.

This indicator reflects the residual value of assets after deducting all liabilities, allowing for an assessment of the actual intrinsic value of each share. The trend of net asset value per share for Enveric Biosciences (ENVB) is critical, as it demonstrates the company's capital resilience against regulatory barriers and raw material supply disruptions, determining the long-term investment attractiveness of the biopharmaceutical business.